GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On April9, 2018, GTx,Inc. issued a press release announcing that it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence.

A copy of the press release is furnished as Exhibit99.1 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued by GTx,Inc. dated April9, 2018


GTX INC /DE/ Exhibit
EX-99.1 2 a18-9799_1ex99d1.htm EX-99.1 Exhibit 99.1   GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial,…
To view the full exhibit click here

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

An ad to help with our costs